Dainippon To Pay Up To $2.6B For Cancer Drug Developer
Dainippon Sumitomo Pharma Co. Ltd. has struck a deal to buy Boston Biomedical Inc., a developer of promising cancer stem cell anti-tumor drugs, for $200 million up front plus milestone payments...To view the full article, register now.
Already a subscriber? Click here to view full article